Potential of first trimester plasma lipidome in high-risk pregnancy groups
- Authors: Minaeva E.A.1, Starodubtseva N.L.1, Shmakov R.G.1, Chagovets V.V.1, Tokareva A.O.1, Novoselova A.V.1, Kukaev E.N.1,2, Frankevich V.E.1,3
-
Affiliations:
- Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation
- V.L. Talrose Institute for Energy Problems of Chemical Physics at N.N. Semenov Federal Research Center for Chemical Physics Russian Academy of Sciences
- Siberian State Medical University, Ministry of Health of the Russian Federation
- Issue: No 10 (2023)
- Pages: 108-118
- Section: Original Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/624718
- DOI: https://doi.org/10.18565/aig.2023.229
- ID: 624718
Cite item
Open Access
Access granted
Abstract
Objective: To evaluate the relationship between plasma lipids, changes in their concentration during early pregnancy, and the risk of preeclampsia (PE) in pregnant women at a high risk for placenta-mediated complications.
Materials and methods: This prospective case-control study included 66 pregnant women, including a group at high risk for placenta-associated complications based on medical history and first trimester screening (n=38) and a control group (n=28). Lipid extracts of blood plasma from the first trimester of pregnancy were analyzed using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Lipids were identified using Lipid Match R-script by accurate mass using the Lipid Maps database and characteristic tandem mass spectra (MS/MS). Based on lipids identified as having a statistically significant correlation with clinical data (Spearman's criterion), a model of projections to latent structures was constructed using two predictive axes. From lipids with a variable projection value greater than 1 in the model, those with which the model based on logistic regression had the lowest Akaike information criterion and coefficients that were significantly different from zero were selected.
Results: Correlation analysis according to high-risk groups identified 48 lipids, for which the level of correlation with at least one clinical parameter was average or above average (R>0.6), belonging to the classes of phosphatidylcholines, phosphatidylinositols, sphingomyelins, and triglycerides. Two logistic regression models were constructed to identify patients at high risk for PE by plasma lipid levels in the first trimester of pregnancy with optimal sensitivity and specificity of 0.91 and 0.91 for the positive ion regimen (phosphatidylethanolamine PE 16:0_22:6 and phosphatidylcholine PC 18:0_18:1) and optimal sensitivity and specificity of 0.82 and 0.96 for the negative ion mode (sphingomyelins SM d24:0/18:1 and SM d22:1/20:4). Survival function analysis yielded a relative risk for the group defined as high-risk using the model based on lipid profile in the positive ion mode of 33.5 with CI 4.7–241, and a relative risk for the PE screening outcome of 2.67 with CI 0.74–9.64.
Conclusion: Changes in the first-trimester plasma lipid spectrum, mainly phosphatidylcholines, lysophosphatidylcholines, phosphatidylethanolamine, triglycerides, and sphingomyelins, are associated with the risk of PE in the high-risk group. This allows us to propose logistic regression models based on first-trimester plasma marker lipid levels as a refinement after the first-trimester screening. In the future, the data obtained may contribute to the improvement of preventive measures for placenta-associated disorders and the timely monitoring of their development.
Full Text
About the authors
Ekaterina A. Minaeva
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation
Author for correspondence.
Email: minaevakatya93@yandex.ru
ORCID iD: 0000-0001-8555-6670
post-graduate student, 1st Obstetric Department of Pregnancy Pathology
Russian Federation, MoscowNatalia L. Starodubtseva
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation
Email: n_starodubtseva@oparina4.ru
ORCID iD: 0000-0001-6650-5915
PhD (Bio.), Head of the Laboratory of Clinical Proteomics
Russian Federation, MoscowRoman G. Shmakov
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation
Email: r_shmakov@oparina4.ru
ORCID iD: 0000-0002-2206-1002
Dr. Med. Sci., Professor, Professor of the Russian Academy of Sciences, Director of the Institute of Obstetrics
Russian Federation, MoscowVitaliy V. Chagovets
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation
Email: vvchagovets@gmail.com
PhD, Head of the Laboratory of Metabolomics and Bioinformatics
Russian Federation, MoscowAlisa O. Tokareva
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation
Email: a_tokareva@oparina4.ru
PhD, specialist at the Laboratory of Clinical Proteomics
Russian Federation, MoscowAnastasia V. Novoselova
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation
Email: a_novoselova@oparina4.ru
Junior Researcher at the Laboratory of Metabolomics and Bioinformatics
Russian Federation, MoscowEvgeny N. Kukaev
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation; V.L. Talrose Institute for Energy Problems of Chemical Physics at N.N. Semenov Federal Research Center for Chemical Physics Russian Academy of Sciences
Email: e_kukaev@oparina4.ru
PhD, Senior Researcher at the Laboratory of Clinical Proteomics
Russian Federation, Moscow; MoscowVladimir E. Frankevich
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation; Siberian State Medical University, Ministry of Health of the Russian Federation
Email: v_vfrankevich@oparina4.ru
ORCID iD: 0000-0002-9780-4579
Dr. Sci. (Physico-Mathematical), Deputy Director of the Institute of Translational Medicine
Russian Federation, Moscow; TomskReferences
- Duley L. The global impact of pre-eclampsia and eclampsia. Semin. Perinatol. 2009; 33(3): 130-7. https://dx.doi.org/10.1053/j.semperi.2009.02.010.
- Moutquin J.-M. Classification and heterogeneity of preterm birth. BJOG. 2003; 110(Suppl.): 30-3. https://dx.doi.org/10.1016/s1470-0328(03)00021-1.
- Ilekis J.V., Reddy U.M., Roberts J.M. Preeclampsia--a pressing problem: an executive summary of a National Institute of Child Health and Human Development workshop. Reprod. Sci. 2007; 14(6): 508-23. https://dx.doi.org/10.1177/1933719107306232.
- Osmond C., Barker D.J. Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women. Environ. Health Perspect. 2000; 108 l3(Suppl 3): 545-53. https://dx.doi.org/10.1289/ehp.00108s3545.
- Chen C.W., Jaffe I.Z., Karumanchi S.A. Pre-eclampsia and cardiovascular disease. Cardiovasc. Res. 2014; 101(4): 579-86. https://dx.doi.org/10.1093/cvr/cvu018.
- Ahmed R., Dunford J., Mehran R., Robson S., Kunadian V. Pre-eclampsia and future cardiovascular risk among women: a review. J. Am. Coll. Cardiol. 2014; 63(18): 1815-22. https://dx.doi.org/10.1016/j.jacc.2014.02.529.
- Mosca L., Benjamin E.J., Berra K., Bezanson J.L., Dolor R.J., Lloyd-Jones D.M. et al.; American Heart Association. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association. J. Am. Coll. Cardiol. 2011; 57(12): 1404-23. https://dx.doi.org/10.1016/j.jacc.2011.02.005.
- Leslie M.S., Briggs L.A. Preeclampsia and the risk of future vascular disease and mortality: a review. J. Midwifery Womens Health. 2016; 61(3): 315-24. https://dx.doi.org/10.1111/jmwh.12469.
- Al-Nasiry S., Ghossein-Doha C., Polman S.E.J., Lemmens S., Scholten R.R., Heidema W.M. et al. Metabolic syndrome after pregnancies complicated by pre-eclampsia or small-for-gestational-age: a retrospective cohort. BJOG. 2015; 122(13): 1818-23. https://dx.doi.org/10.1111/1471-0528.13117.
- Muttukrishna S., Knight P.G., Groome N.P., Redman C.W., Ledger W.L. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet. 1997; 349(9061): 1285-8. https://dx.doi.org/10.1016/S0140-6736(96)09264-1.
- Birdsall M., Ledger W., Groome N., Abdalla H., Muttukrishna S. Inhibin A and activin A in the first trimester of human pregnancy J. Clin. Endocrinol. Metab. 1997; 82(5): 1557-60. https://dx.doi.org/10.1210/jcem.82.5.3934.
- Aitken D.A., Wallace E.M., Crossley J.A., Swanston I.A., van Pareren Y., van Maarle M. et al. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. N. Engl. J. Med. 1996; 334(19): 1231-6. https://dx.doi.org/10.1056/NEJM199605093341904.
- Wu P., van den Berg C., Alfirevic Z., O'Brien S., Rothlisberger M., Baker P.N. et al. Early pregnancy biomarkers in pre-eclampsia: a systematic review and meta-analysis. Int. J. Mol. Sci. 2015; 16(9): 23035-56. https://dx.doi.org/10.3390/ijms160923035.
- Tornehave D., Folkersen J., Teisner B., Chemnitz J. Immunohistochemical aspects of immunological cross-reaction and masking of epitopes for localization studies on pregnancy-associated plasma protein A. Histochem. J. 1986; 18(4): 184-8. https://dx.doi.org/10.1007/BF01676119.
- Smith G.C.S., Stenhouse E.J., Crossley J.A., Aitken D.A., Cameron A.D., Connor J.M. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J. Clin. Endocrinol. Metab. 2002; 87(4): 1762-7. https://dx.doi.org/10.1210/jcem.87.4.8430.
- Ranta J.K., Raatikainen K., Romppanen J., Pulkki K., Heinonen S. Decreased PAPP-A is associated with preeclampsia, premature delivery and small for gestational age infants but not with placental abruption Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 157(1): 48-52. https://dx.doi.org/10.1016/ j.ejogrb.2011.03.004.
- Wang H.Y., Zhang Z., Yu S. Expression of PAPPA2 in human fetomaternal interface and involvement in trophoblast invasion and migration. Genet. Mol. Res. 2016; 15(3). https://dx.doi.org/10.4238/gmr.15038075.
- Кан Н.Е., Ломова Н.А., Амирасланов Э.Ю., Чаговец В.В., Тютюнник В.Л., Хачатрян З.В., Стародубцева Н.Л., Кициловская Н.А., Франкевич В.Е. Особенности метаболомного профиля при преэклампсии. Акушерство и гинекология. 2019; 11: 82-8. [Kan N.E., Lomova N.A., Amiraslanov E.Yu., Chagovets V.V., Tyutyunnik V.L., Khachatryan Z.V., Starodubtseva N.L., Kitsilovskaya N.A., Frankevich V.E. Specific features of a metabolomic profile in preeclampsia. Obstetrics and Gynecology. 2019; (11): 82-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2019.11.82-88.
- Kononikhin A., Zakharova N.V., Sergeeva V.A., Indeykina M.I., Starodubtseva N.L., Bugrova A.E. et al. Differential diagnosis of preeclampsia based on urine peptidome featches revealed by high resolution mass spectrometry. Diagnostics (Basel). 2020; 10(12): 1039. https://dx.doi.org/10.3390/diagnostics10121039.
- Tarca A.L., Romero R., Benshalom-Tirosh N., Than N.G., Gudicha D.W., Done B. et al. The prediction of early preeclampsia: Results from a longitudinal proteomics study. PLoS One. 2019; 14(6): e0217273. https://dx.doi.org/10.1371/journal.pone.0217273.
- Сергеева В.А., Муминова К., Стародубцева Н.Л., Кононихин А.С., Бугрова А.Е., Индейкина М.И., Байбакова В.В., Ходжаева З.С., Кан Н.Е., Франкевич В.Е., Шмаков Р.Г., Николаев Е.Н., Сухих Г.Т. Особенности пептидома мочи при гипертензивных патологиях беременных. Биомедицинская химия. 2017; 63(5): 379-84. [Sergeeva V.A., Muminova K.T., Starodubtseva N.L., Kononikhin A.S., Bugrova A.E., Indeykina M.I., Baibakova V.V., Khodzhaeva Z.S., Kan N.E., Frankevich V.E., Shmakov R.G., Nikolaev E.N., Sukhikh G.T. Features of the urine peptidome under the condition of hypertensive pathologies of pregnancy. Biomeditsinskaya Khimiya. 2017; 63(5): 379-84. (in Russian)].
- Starodubtseva N., Nizyaeva N., Baev O., Bugrova A., Gapaeva M., Muminova K. et al. SERPINA1 peptides in urine as a potential marker of preeclampsia severity. Int. J. Mol. Sci. 2020; 21(3): 914. https://dx.doi.org/10.3390/ijms21030914.
- Booth R.A., Hill S.A., Don-Wauchope A., Santaguida P.L., Oremus M., McKelvie R. et al. Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. Heart Fail. Rev. 2014; 19(4): 439-51. https://dx.doi.org/10.1007/s10741-014-9445-8.
- Verlohren S., Perschel F.H., Thilaganathan B., Dröge L.A., Henrich W., Busjahn A., Khalil A. Angiogenic markers and cardiovascular indices in the prediction of hypertensive disorders of pregnancy. Hypertension. 2017; 69(6): 1192-7. https://dx.doi.org/10.1161/HYPERTENSIONAHA.117.09256.
- Giannubilo S.R., Pasculli A., Tidu E., Biagini A., Boscarato V., Ciavattini A. Relationship between maternal hemodynamics and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia and fetal growth restriction. J. Perinatol. 2017; 37(5): 484-7. https://dx.doi.org/10.1038/jp.2016.264.
- El Khouly N.I., Sanad Z.F., Saleh S.A., Shabana A.A., Elhalaby A.F., Badr E.E. Value of first-trimester serum lipid profile in early prediction of preeclampsia and its severity: A prospective cohort study. Hypertens Pregnancy. 2016; 35(1): 73-81. https://dx.doi.org/10.3109/10641955.2015.1115060.
- Korkes H.A., Sass N., Moron A.F., Câmara N.O.S., BonettI T., Cerdeira A.S. et al. Lipidomic assessment of plasma and placenta of women with early-onset preeclampsia. PLoS One. 2014; 9(10): e110747. https://dx.doi.org/10.1371/journal.pone.0110747.
- de Lima V.J., de Andrade C.R., Ruschi G.E., Sass N. Serum lipid levels in pregnancies complicated by preeclampsia. Sao Paulo Med. J. 2011; 129(2): 73-6. https://dx.doi.org/10.1590/s1516-31802011000200004.
- Yu L., Li D., Liao Q.-P., Yang H.-X., Cao B., Fu G. et al. High levels of activin a detected in preeclamptic placenta induce trophoblast cell apoptosis by promoting nodal signaling. J. Clin. Endocrinol. Metab. 2012; 97(8): E1370-9. https://dx.doi.org/10.1210/jc.2011-2729.
- Gofman J.W., Delalla O., Glazier F., Freeman N.K., Lindgren F.T., Nichols A.V. et al. The serum lipoprote in transport system in health, metabolic disorders, atherosclerosis and coronary heart disease. J. Clin. Lipidol. 2011; 1(2): 104-41. https://dx.doi.org/10.1016/j.jacl.2007.03.001.
- Ahmed A.A.M., El Omda F.A.A., Mousa M.S.M. Maternal lipid profile as a risk factor for preeclampsia. Egyp. J. Hosp. Med. 2018; 71(6): 3434-8. https://dx.doi.org/10.12816/0047307.
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Преэклампсия. Эклампсия. Отеки, протеинурия и гипертензивные расстройства во время беременности, в родах и послеродовом периоде. 2021. [Ministry of Health of the Russian Federation. Clinical guidelines. Preeclampsia. Eclampsia. Edema, proteinuria, and hypertensive disorders during pregnancy, childbirth, and postpartum. 2021.(in Russian)].
Supplementary files
